Testosterone and doping control

British Journal of Sports Medicine

Volumn 40, Issue SUPPL. 1, 2006, Pages

  Saudan, C ^a   Baume, N ^a   Robinson, N ^a   Avois, L ^a   Mangin, P ^a   Saugy, M ^a  

^a UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIOL; ANDROSTENEDIONE; BOLDENONE; CARBON; DROSTANOLONE; EPITESTOSTERONE; METANDIENONE; METENOLONE; METHYLTESTOSTERONE; NANDROLONE; OXANDROLONE; OXYMESTERONE; PRASTERONE; STANOZOLOL; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TRENBOLONE;

ANXIETY; CONFUSION; DOPING; DRUG DETERMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EUPHORIA; GAS CHROMATOGRAPHY; HALLUCINATION; HUMAN; INSOMNIA; MASS SPECTROMETRY; MUSCLE GROWTH; PARANOIA; PROTEIN SYNTHESIS; REVIEW; SIDE EFFECT; SPORTS MEDICINE; STEROID URINE LEVEL;

ADMINISTRATION, ORAL; ANDROGENS; BIOLOGICAL MARKERS; DOPING IN SPORTS; HUMANS; INJECTIONS, INTRAMUSCULAR; SUBSTANCE ABUSE DETECTION; TESTOSTERONE;

EID: 33745809866     PISSN: 03063674     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjsm.2006.027482     Document Type: Review

References (43)

1. Wynn V. Metabolic effects of anabolic steroids. Br J Sports Med 1975;9:60-4.
2. Milgrom E. Steroid hormones. In: Baulieu E-E, Kelly PA, eds. Hormones: From Molecules to Disease. Paris: Hermann, 1990:385-442.
3. Wilson JD, Griffin JE. The use and misuse of androgens. Metabolism 1980;29:1278-95.
4. Nieschlag E, Mauss J, Coert A, et al. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol 1975;79:366-74.
5. Coert A, Geelen J, de Visser J, et al. The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen. Acta Endocrinol 1975;79:789-800.
6. Handelsman DJ. Androgen action and pharmacologic uses. In: DeGroot U, Jameson JL, eds. Endocrinology. WB Saunders, Philadelphia, 2000:2232-42.
7. Janne OA, Palvimo JJ, Kallio P, et al. Androgen receptor and mechanism of androgen action. Ann Med 1993;25:83-9.
8. Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:55-69.
9. Kuhn CM. Anabolic steroid. Recent Progres Horm Res 2002;57:411-34.
10. Basaria S, Wahlstrom JT, Dobs A. Clinical review 138. Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001;86:5108-17.
11. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984;12:469-84.
12. Hartgens F, van Straaten H, Fideldij S, et al. Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: differences between polydrug regimens and single drug administration. Eur J Appl Physiol 2002;86:233-9.
13. Evans NA. Current concept in anabolic-androgenic steroids. Am J Sports Med 2004;32:534-42.
14. Blue JG, Lombardo JA. Steroids and steroid-like compounds. Clin Sports Med 1999;18:667-89.
15. Perry PJ, Andersen KH, Yates WR. Illicit anabolic steroid use in athletes. A case series analysis. Am J Sports Med 1990;18:422-8.
16. Rogol AD, Yesalis CE. Clinical Review 31. Anabolic-androgenic steroids and athletes: what are the issues, J Clin Endocrinol Metab 1992;74:465-9.
17. O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 2004;89:2837-45.
18. Baume N, Seiler R, Birrer D, et al. Evaluation of mood states following anabolic androgenic steroid oral intake combined with one month endurance training. Psychol Sport Exer (in press).
19. World Anti-Doping Agency. The 2006 Prohibited List. International standards. World Anti-Doping Code. Montreal: WADA, 2005, Available at:www.wada-ama.org/rtecontent/document/2006_LIST.pdf (accessed 19 September 2005).
20. Ayotte C, Goudreault D, Charlebois A. Testing for natural and synthetic anabolic agents in human urine. J Chromatogr B 1996;687:3-25.
21. Saugy M, Cardis C, Robinson N, et al. Test methods: anabolics. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:111-33.
22. Donike ML, Bärwald KR, Klosterman K, et al. Nachweis von exogenem Testosteron. In: Heck H, Hollman W, Liesen H, et al. Sport: Leistung und Gesundheit. Köln, Germany: Deutscher Artze-Verlag, 1982:293-300.
23. Catlin DH, Hatton CK, Starcevic SH. Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Clin Chem 1997;43:1280-8.
24. van de Kerkhof DH, de Boer D, Thijssen JHH, et al. Evaluation of testosterone/epitestosterone ratio influential factors as determined in doping analysis. J Anal Toxicol 2000;24:102-15.
25. Oftebro H, Jensen J, Mowinckel P, et al. Establishing a ketoconazole suppression test for verifying testosterone administration in the doping control of athletes. J Clin Endocrinol Metab 1994;78:973-7.
26. Kicman AT, Brooks RV, Collyer SC, et al. Criteria to indicate testosterone administration. Br J Sports Med 1990;24:253-64.
27. Carlström K, Palonek E, Garle M, et al. Detection of testosterone administration by increased ratio between serum concentrations of testosterone and 17 alpha-hydroxyprogesterone. Clin Chem 1992;38:1779-84.
28. Kintz P, Cirimele V, Jeanneau T, et al. Identification of testosterone and testosterone esters in human hair. J Anal Toxicol 1999;23:352-6.
29. Segura J, Peng SH, de la Torre X. Recent progress in the detection of the administration of natural hormones: special focus on testosterone. J Toxicol Toxin Rev 1999;18:125-44.
30. Segura J, Pichini S, Peng SH, et al. Hair analysis and detectability of single dose administration of androgenic steroid esters. Forensic Sci Int 2000;107:347-59.
31. WADA Technical Document. Reporting and evaluation guidance for testosterone, epitestosterone, T/E ratio and other endogenous steroids, 2004. Available at: www.wada-ama.org/ (accessed 30 May 2004).
32. 12C isotope ratio MS analysis of testosterone, in chemicals and pharmaceutical preparations. J Pharm Biomed Anal 2001;24:645-50.
33. Platzner IT, Habfast K, Walder AJ, et al. Applications of isotope mass spectrometry. In: Winefordner JD, ed. Modem Isotope Ratio Mass Spectrometry. New York: J Wiley & Sons, 1997:403-47.
34. Tanis AA, Rietveld T, Van Den Berg JWO, et al. Influence of the 13C-enrichment of the habitual diet on a 13CO2 breath test used as an index of liver glycogen oxidation: a validation study in western Europe and Africa. Nutrition 2000;16:6-10.
35. Cawley A, Rogerson J, Rahman K, et al. Preliminary results on the carbon isotope ratios of ketonic steroids in urine samples collected from different countries. In: Schänzer W, Geyer H, Gotzmann A, et al. Recent Advances in Doping Analysis. Köln: Sport und Buch Strauß, 2003:183-93.
36. Maître A, Saudan C, Mangin P, et al. Urinary analysis of four testosterone metabolites and pregnanediol by gas chromatography-combustion- isotope ratio mass spectrometry after oral administrations of testosterone. J Anal Toxicol 2004;28:426-31.
37. Brenna JT, Corso TN, Tobias HJ, et al. High-precision continuous-flow isotope ratio mass spectrometry. Mass Spectrom Rev 1997;16:227-58.
38. Aguilera R, Chapman TE, Starcevic B, et al. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. Clin Chem 2001;47:292-300.
39. Shackleton CHL, Phillips A, Chang T, et al. Confirming testosterone administration by isotope ratio mass spectrometric analysis of urinary androstanediols. Steroids 1997;62:379-87.
40. Saudan C, Baume N, Mangin P, et al. Urinary analysis of 16(5α)-Androsten-3α-ol by gas chromatography/combustion/isotope ratio mass spectrometry: implications in anti-doping analysis. J Chromatogr B 2004;810:157-64.
41. Saudan C, Desmarchelier A, Sottas PE, et al. Urinary marker of oral pregnenolone administration. Steroids 2005;70:179-83.
42. 12C) ratio. Steroids 2006;71:364-70.
43. Aguilera R, Hatton CK, Catlin DH. Detection of epitestosterone doping by isotope ratio mass spectrometry. Clin Chem 2002;48:629-36.